- Home
- PSHG vs TXMD Comparison
PSHG vs TXMD Comparison
Compare PSHG & TXMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PSHG | TXMD |
|---|---|---|
| Founded | 2010 | 2008 |
| Country | Greece | United States |
| Employees | N/A | N/A |
| Industry | Marine Transportation | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 24.7M | 24.4M |
| IPO Year | 2010 | 2012 |
Fundamental Metrics
Financial Performance| Metric | PSHG | TXMD |
|---|---|---|
| Price | $1.73 | $2.12 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 54.0K | 17.0K |
| Earning Date | 05-26-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 73.68 |
| EPS | N/A | ★ 0.01 |
| Revenue | N/A | ★ $1,761,000.00 |
| Revenue This Year | $49.57 | N/A |
| Revenue Next Year | $2.73 | N/A |
| P/E Ratio | ★ $1.59 | $211.00 |
| Revenue Growth | N/A | ★ 35.25 |
| 52 Week Low | $1.58 | $0.98 |
| 52 Week High | $2.58 | $2.95 |
Technical Indicators
Market Signals| Indicator | PSHG | TXMD |
|---|---|---|
| Relative Strength Index (RSI) | 43.73 | 46.30 |
| Support Level | $1.71 | $1.93 |
| Resistance Level | $2.09 | $2.10 |
| Average True Range (ATR) | 0.05 | 0.09 |
| MACD | -0.00 | 0.01 |
| Stochastic Oscillator | 50.00 | 45.83 |
Price Performance
Historical ComparisonAbout PSHG Performance Shipping Inc.
Performance Shipping Inc is a provider of shipping transportation services through its ownership of tanker vessels. The company's vessels are employed on time charters with liner companies carrying containerized cargo along various shipping routes. It owns and operates six Aframax tanker vessels.
About TXMD TherapeuticsMD Inc.
TherapeuticsMD Inc is a pharmaceutical royalty company that owns and manages intellectual property, including trademarks and product rights, which are licensed to third-party pharmaceutical companies. The company generates revenue mainly through royalties and milestone payments from licensed products, including IMVEXXY, BIJUVA, and ANNOVERA, and does not directly manufacture or market pharmaceutical products.